PUBLISHER: Market Xcel - Markets and Data | PRODUCT CODE: 1426134
PUBLISHER: Market Xcel - Markets and Data | PRODUCT CODE: 1426134
Beta Thalassemia Market Assessment, By Type, By Therapy, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F
Global beta thalassemia market is projected to witness a CAGR of 7.75% during the forecast period 2024-2031F, growing from USD 503 million in 2023, to USD 913.92 million in 2031. The market has experienced significant growth in recent years and is expected to maintain a strong pace of expansion in the coming years.
Beta thalassemia is the most common autosomal recessive disorder inherited from parents and characterized by a reduced production of functional hemoglobin due to a mutation in the HBB gene that leads to the deficient or absent synthesis of beta-globin chains. Based on the severity, the disorder is categorized into minor, intermediate, and major types of beta thalassemia. A variety of therapies like blood transfusion, iron chelation therapy, gene therapy, and bone marrow therapy treat the beta thalassemia condition. Bone marrow transplants are most common in patients under the age of 16 years.
The beta thalassemia marktherapies andly influenced by the growing prevalence of beta thalassemia, escalated advancement in therapies, and increasing demand for point-of-care testing. Growing healthcare infrastructure and increased healthcare spending in recent years have significantly supported the beta thalassemia market. Additionally, government initiatives to reduce the blood-related disease burden have positively impacted the demand for relevant products.
Beta thalassemia is most common in low-income regions like Mediterranean, Southeast Asia, the Indian subcontinent, and the Middle East. The migration of people from these regions to high-income countries like the United States has significantly changed the prevalence, for example, the prevalence of beta thalassemia has increased by 7.5% in the last 50 years despite the low number of reported cases. Countries like Italy implemented specific policies for reducing hemoglobinopathies, these initiatives are anticipated to impact the global beta thalassemia market during the assessment period. Alongside, FDA approval of beta thalassemia therapies in recent times has developed healthy competition among the key players.
In January 2024, Vertex Pharmaceuticals Incorporated announced that U.S. Food and Drug Administration (FDA) approved its CASGEVY (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited cell therapy. The therapy is meant for treating transfusion-dependent beta thalassemia (TDT) in patients above the age of 12 years. The therapy is available in the United States for now in hospitals with expertise in stem cell transplantation. CASGEVY has shown a 91.4% success rate in patients with TDT.
Growing Prevalence of Beta Thalassemia
Beta thalassemia has a significant prevalence in South Asia, Middle East, North Africa, and Southern Europe. Population migration is changing the global distribution of disease. The flow of refugee populations from war-affected zones, like Syria and Iraq, is contributing to the disturbance of disease statistics, but beta thalassemia is considered a rare disease. The global prevalence of beta thalassemia is increasing due to a high carrier rate, migration trends, and cultural preference for consanguineous marriages. With the increasing prevalence of beta thalassemia, the demand for its treatment is anticipated to rise during the forecast period.
As per 'Global Thalassemia Review - 2023' published by Thalassemia International Federation estimates, 5-7% of the global population is the carrier of mutated genes affecting the production or function of the hemoglobin in the body. It suggests that over 330,000 affected infants are born annually out of which 83% have sickle cell disorders and 17% are thalassemia (counting around 56,000 infants).
Escalated Advancement in Therapies
Conventional therapies for beta thalassemia, such as transfusion and iron chelation, have several limitations, however, recent advancements in beta thalassemia therapies have led to improved therapies that can be categorized into three major categories, correction of the globin chain imbalance, addressing ineffective erythropoiesis, and improving iron overload. These emerging therapies include investigational erythroid maturation agents, gene therapy, and embryonic-like stem cells obtained by somatic cell nuclear transfer. Ongoing clinical trials of gene editing and agents modulating iron metabolism promise new improvements. Patients with beta thalassemia have several therapeutic options nowadays, further strengthening the beta thalassemia market.
For example, in August 2023, the U.S. FDA approved Bristol Myers Squibb's Reblozyl (luspatercept-aamt) for providing first-line treatment of anemia in adults with lower-risk myelodysplastic syndromes requiring transfusions. Reblozyl is commercialized through global collaboration between Bristol Mayer Squibb and Merck since November 2021. With this approval, Reblozyl is now approved in the United States for patients of anemia, beta thalassemia, and myelodysplastic syndromes.
Focus of Regulatory Bodies to Catalyze the Market
Regulatory bodies play a crucial role in catalyzing the beta thalassemia market by evaluating and approving novel therapies. The focus of regulatory bodies on emerging treatments can improve the availability of novel treatment options for patients. For instance, the approval of gene therapies such as ZYNTEGLO, which introduces functional, engineered copies of beta-globin genes, represents a significant milestone in the treatment of beta thalassemia. Additionally, the regulatory support for novel genetic therapies and the combination of CRISPR/Cas9 and induced pluripotent stem cell (IPSC) technologies in gene therapy demonstrate the potential for regulatory bodies to foster advancements in the field. By providing a clear pathway for developing and approving these innovative therapies, regulatory bodies can improvise the research and development, ultimately expanding the treatment landscape for beta thalassemia.
For example, in March 2023, Bristol Myers Squibb received European Commission approval for Reblozyl (luspatercept) for anemia in adult patients with non-transfusion-dependent beta thalassemia. After the approval, Reblozyl is approved and available in the European Union (EU), the United States, and Canada for treating beta thalassemia patients. The European Commission approved it based on the phase 2 BEYOND study, which proved the efficacy and safety of Reblozyl versus placebo in 145 patients.
Blood Transfusion Segment Dominate the Market
Blood transfusion is the most common type of therapy for beta thalassemia. In more severe cases, such as beta thalassemia major, some patients may require periodic blood transfusions known as transfusion-dependent thalassemia. Blood transfusions help to increase the number of red blood cells in the body and improve oxygen delivery to the tissues. However, regular blood transfusions can lead to iron overload, which can damage vital organs like the liver, heart, and pancreas, but is proven effective in beta thalassemia patients. Therefore, iron chelation therapy may be necessary to remove excess iron from the body. Several conjunctive therapies are provided in addition to blood transfusion to increase efficacy. For instance, as per an article published in PubMed in April 2023, the study conducted among transfusion-dependent thalassemia patients showed that conjunctive therapy of hydroxyurea significantly increases the time interval between transfusions as well as improves the hemoglobin level in these patients.
Hospital Pharmacies are the Leading Distribution Channel
The hospital pharmacies segment is anticipated to be the leading distribution channel for beta thalassemia treatments. Hospitals are major centers for beta thalassemia drugs due to the complex medical management required for this condition. Patients with beta thalassemia often need routine blood transfusions, iron chelation therapy, and potentially curative treatments, which demand extensive medical supervision. Additionally, hospitals are equipped to handle the specialized care and monitoring associated with these treatments, making them primary location for administering and managing beta thalassemia therapies.
North America Dominates Beta Thalassemia Market
North America is anticipated to be the leading region in the beta thalassemia market with the highest market share. The dominance of North America is governed by factors like the strong presence of major players in the market and is characterized by increasing healthcare expenditure, rising cases of thalassemia, a growing number of research activities, high disposable income of the region, high healthcare expenditure, and government initiatives to reduce hemoglobinopathies. Presently, the most approved gene therapies are approved in the United States and Canada, contributing the major share of revenue to the beta thalassemia market. Asia-Pacific and Middle East and Africa are anticipated to grow with high CAGR due to large opportunities in untapped markets and the rising prevalence of beta thalassemia.
Future Market Scenario (2024 - 2031F)
Growing prevalence of beta thalassemia due to migration trends and changes in disease distribution patterns are majorly driving the growth in the beta thalassemia market.
Advancements in beta thalassemia therapies such as investigational erythroid maturation agents, gene therapy, and embryonic-like stem cells drastically contribute to the beta thalassemia market.
Regulatory emphasis on the development and approval of novel therapies for beta thalassemia is leading to an increase in the number of commercialized products which is anticipated to contribute towards the future growth of the market.
Blood transfusion segment is anticipated to dominate therapy type in the beta thalassemia market due to high efficacy and cost-effectiveness.
Key Players Landscape and Outlook
Key participants in the beta thalassemia market include Bluebird Bio, Inc., Bristol-Myers Squibb Co., and Vertex Pharmaceuticals Incorporated. The market caters to several pharmaceutical and biotechnology companies and startups. These companies are involved in the development and commercialization of various treatments and therapies for beta thalassemia. The players in this market are actively involved in product development and approvals, collaboration, and other market tactics. Several players have promising product pipelines and therapies under different phases of clinical trials.
For instance, Shanghai BDgene Co., Ltd., Shenzhen Hemogen, Editas Medicine, Inc., Vertex Pharmaceuticals Incorporated, Bristol-Myers Squibb, Editas Medicine, Inc., CorrectSequence Therapeutics Co., Ltd, are some market players that have genetic and biological products under clinical investigation, presently.
In November 2023, MHRA authorized the world's first gene therapy (Casgevy) to cure sickle-cell anemia and transfusion-dependent B-thalassemia. The therapy was developed by CRISPR therapeutics. Casgevy is the first approved medicine that utilizes the innovative gene-editing technique CRISPR, for which its inventors were awarded the Nobel Prize in 2020.
Table of Contents
1. Research Methodology
2. Project Scope & Definitions
3. Executive Summary
4. Global Beta Thalassemia Market Outlook, 2017-2031F
- 4.1. Market Size & Forecast
- 4.1.1. By Value
- 4.1.2. By Volume
- 4.2. By Type
- 4.2.1. Beta Thalassemia Minor
- 4.2.2. Beta Thalassemia Intermedia
- 4.2.3. Beta Thalassemia Major
- 4.3. By Therapy
- 4.3.1. Blood Transfusions
- 4.3.2. Iron Chelation Therapy
- 4.3.3. Folic Acid Supplements
- 4.3.4. Gene Therapy
- 4.3.5. Bone Marrow Transplants
- 4.4. By Distribution Channel
- 4.4.1. Hospital Pharmacies
- 4.4.2. Retail Pharmacies
- 4.4.3. Online Pharmacies
- 4.5. By Region
- 4.5.1. North America
- 4.5.2. Europe
- 4.5.3. Asia-Pacific
- 4.5.4. South America
- 4.5.5. Middle East and Africa
- 4.6. By Company Market Share (%), 2023
5. Global Beta Thalassemia Market Outlook, By Region, 2017-2031F
- 5.1. North America*
- 5.1.1. Market Size & Forecast
- 5.1.1.1. By Value
- 5.1.1.2. By Volume
- 5.1.2. By Type
- 5.1.2.1. Beta Thalassemia Minor
- 5.1.2.2. Beta Thalassemia Intermedia
- 5.1.2.3. Beta Thalassemia Major
- 5.1.3. By Therapy
- 5.1.3.1. Blood Transfusions
- 5.1.3.2. Iron Chelation Therapy
- 5.1.3.3. Folic Acid Supplements
- 5.1.3.4. Gene Therapy
- 5.1.3.5. Bone Marrow Transplants
- 5.1.4. By Distribution Channel
- 5.1.4.1. Hospital Pharmacies
- 5.1.4.2. Retail Pharmacies
- 5.1.4.3. Online Pharmacies
- 5.1.5. United States*
- 5.1.5.1. Market Size & Forecast
- 5.1.5.1.1. By Value
- 5.1.5.1.2. By Volume
- 5.1.5.2. By Type
- 5.1.5.2.1. Beta Thalassemia Minor
- 5.1.5.2.2. Beta Thalassemia Intermedia
- 5.1.5.2.3. Beta Thalassemia Major
- 5.1.5.3. By Therapy
- 5.1.5.3.1. Blood Transfusions
- 5.1.5.3.2. Iron Chelation Therapy
- 5.1.5.3.3. Folic Acid Supplements
- 5.1.5.3.4. Gene Therapy
- 5.1.5.3.5. Bone Marrow Transplants
- 5.1.5.4. By Distribution Channel
- 5.1.5.4.1. Hospital Pharmacies
- 5.1.5.4.2. Retail Pharmacies
- 5.1.5.4.3. Online Pharmacies
- 5.1.6. Canada
- 5.1.7. Mexico
- 5.1.1. Market Size & Forecast
All segments will be provided for all regions and countries covered
- 5.1. Europe
- 5.1.6. Germany
- 5.1.7. France
- 5.1.8. Italy
- 5.1.9. United Kingdom
- 5.1.10. Russia
- 5.1.11. Netherlands
- 5.1.12. Spain
- 5.1.13. Turkey
- 5.1.14. Poland
- 5.2. Asia-Pacific
- 5.2.6. India
- 5.2.7. China
- 5.2.8. Japan
- 5.2.9. Australia
- 5.2.10. Vietnam
- 5.2.11. South Korea
- 5.2.12. Indonesia
- 5.2.13. Philippines
- 5.3. South America
- 5.3.6. Brazil
- 5.3.7. Argentina
- 5.4. Middle East & Africa
- 5.4.6. Saudi Arabia
- 5.4.7. UAE
- 5.4.8. South Africa
6. Market Mapping, 2023
- 6.1. By Type
- 6.2. By Therapy
- 6.3. By Distribution Channel
- 6.4. By Region
7. Macro Environment and Industry Structure
- 7.1. Demand Supply Analysis
- 7.2. Import Export Analysis
- 7.3. Value Chain Analysis
- 7.4. PESTEL Analysis
- 7.4.6. Political Factors
- 7.4.7. Economic System
- 7.4.8. Social Implications
- 7.4.9. Technological Advancements
- 7.4.10. Environmental Impacts
- 7.4.11. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
- 7.5. Porter's Five Forces Analysis
- 7.5.6. Supplier Power
- 7.5.7. Buyer Power
- 7.5.8. Substitution Threat
- 7.5.9. Threat from New Entrant
- 7.5.10. Competitive Rivalry
8. Market Dynamics
- 8.1. Growth Drivers
- 8.2. Growth Inhibitors (Challenges and Restraints)
9. Regulatory Framework and Innovation
- 9.1. Clinical Trials
- 9.2. Patent Landscape
- 9.3. Regulatory Approvals
- 9.4. Innovations/Emerging Technologies
10. Key Players Landscape
- 10.1. Competition Matrix of Top Five Market Leaders
- 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
- 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
- 10.4. SWOT Analysis (For Five Market Players)
11. Case Studies
12. Key Players Outlook
- 12.1. Bluebird Bio, Inc.
- 12.1.1. Company Details
- 12.1.2. Key Management Personnel
- 12.1.3. Products & Services
- 12.1.4. Financials (As reported)
- 12.1.5. Key Market Focus & Geographical Presence
- 12.1.6. Recent Developments
- 12.2. Bristol-Myers Squibb Co
- 12.3. GlaxoSmithKline plc
- 12.4. Incyte Corporation
- 12.5. CRISPR Therapeutics AG
- 12.6. Ionis Pharmaceuticals Inc
- 12.7. Vertex Pharmaceuticals Incorporated
- 12.8. Apotex Inc.
- 12.9. Novartis International AG
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.
13. Strategic Recommendations
14. About Us & Disclaimer
List of Tables
- Table 1. Pricing Analysis of Products from Key Players
- Table 2. Competition Matrix of Top 5 Market Leaders
- Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
- Table 4. About Us - Regions and Countries Where We Have Executed Client Projects
List of Figures
- Figure 1. Global Beta Thalassemia Market, By Value, in USD Million, 2017-2031F
- Figure 2. Global Beta Thalassemia Market, By Volume, in Number of Patients, 2017-2031F
- Figure 3. Global Beta Thalassemia Market Share (%), By Type, 2017-2031F
- Figure 4. Global Beta Thalassemia Market Share (%), By Therapy, 2017-2031F
- Figure 5. Global Beta Thalassemia Market Share (%), By Distribution Channel, 2017-2031F
- Figure 6. Global Beta Thalassemia Market Share (%), By Region, 2017-2031F
- Figure 7. North America Beta Thalassemia Market, By Value, in USD Million, 2017-2031F
- Figure 8. North America Beta Thalassemia Market, By Volume, in Number of Patients, 2017-2031F
- Figure 9. North America Beta Thalassemia Market Share (%), By Type, 2017-2031F
- Figure 10. North America Beta Thalassemia Market Share (%), By Therapy, 2017-2031F
- Figure 11. North America Beta Thalassemia Market Share (%), By Distribution Channel, 2017-2031F
- Figure 12. North America Beta Thalassemia Market Share (%), By Country, 2017-2031F
- Figure 13. United States Beta Thalassemia Market, By Value, in USD Million, 2017-2031F
- Figure 14. United States Beta Thalassemia Market, By Volume, in Number of Patients, 2017-2031F
- Figure 15. United States Beta Thalassemia Market Share (%), By Type, 2017-2031F
- Figure 16. United States Beta Thalassemia Market Share (%), By Therapy, 2017-2031F
- Figure 17. United States Beta Thalassemia Market Share (%), By Distribution Channel, 2017-2031F
- Figure 18. Canada Beta Thalassemia Market, By Value, in USD Million, 2017-2031F
- Figure 19. Canada Beta Thalassemia Market, By Volume, in Number of Patients, 2017-2031F
- Figure 20. Canada Beta Thalassemia Market Share (%), By Type, 2017-2031F
- Figure 21. Canada Beta Thalassemia Market Share (%), By Therapy, 2017-2031F
- Figure 22. Canada Beta Thalassemia Market Share (%), By Distribution Channel, 2017-2031F
- Figure 23. Mexico Beta Thalassemia Market, By Value, in USD Million, 2017-2031F
- Figure 24. Mexico Beta Thalassemia Market, By Volume, in Number of Patients, 2017-2031F
- Figure 25. Mexico Beta Thalassemia Market Share (%), By Type, 2017-2031F
- Figure 26. Mexico Beta Thalassemia Market Share (%), By Therapy, 2017-2031F
- Figure 27. Mexico Beta Thalassemia Market Share (%), By Distribution Channel, 2017-2031F
- Figure 28. Europe Beta Thalassemia Market, By Value, in USD Million, 2017-2031F
- Figure 29. Europe Beta Thalassemia Market, By Volume, in Number of Patients, 2017-2031F
- Figure 30. Europe Beta Thalassemia Market Share (%), By Type, 2017-2031F
- Figure 31. Europe Beta Thalassemia Market Share (%), By Therapy, 2017-2031F
- Figure 32. Europe Beta Thalassemia Market Share (%), By Distribution Channel, 2017-2031F
- Figure 33. Europe Beta Thalassemia Market Share (%), By Country, 2017-2031F
- Figure 34. Germany Beta Thalassemia Market, By Value, in USD Million, 2017-2031F
- Figure 35. Germany Beta Thalassemia Market, By Volume, in Number of Patients, 2017-2031F
- Figure 36. Germany Beta Thalassemia Market Share (%), By Type, 2017-2031F
- Figure 37. Germany Beta Thalassemia Market Share (%), By Therapy, 2017-2031F
- Figure 38. Germany Beta Thalassemia Market Share (%), By Distribution Channel, 2017-2031F
- Figure 39. France Beta Thalassemia Market, By Value, in USD Million, 2017-2031F
- Figure 40. France Beta Thalassemia Market, By Volume, in Number of Patients, 2017-2031F
- Figure 41. France Beta Thalassemia Market Share (%), By Type, 2017-2031F
- Figure 42. France Beta Thalassemia Market Share (%), By Therapy, 2017-2031F
- Figure 43. France Beta Thalassemia Market Share (%), By Distribution Channel, 2017-2031F
- Figure 44. Italy Beta Thalassemia Market, By Value, in USD Million, 2017-2031F
- Figure 45. Italy Beta Thalassemia Market, By Volume, in Number of Patients, 2017-2031F
- Figure 46. Italy Beta Thalassemia Market Share (%), By Type, 2017-2031F
- Figure 47. Italy Beta Thalassemia Market Share (%), By Therapy, 2017-2031F
- Figure 48. Italy Beta Thalassemia Market Share (%), By Distribution Channel, 2017-2031F
- Figure 49. United Kingdom Beta Thalassemia Market, By Value, in USD Million, 2017-2031F
- Figure 50. United Kingdom Beta Thalassemia Market, By Volume, in Number of Patients, 2017-2031F
- Figure 51. United Kingdom Beta Thalassemia Market Share (%), By Type, 2017-2031F
- Figure 52. United Kingdom Beta Thalassemia Market Share (%), By Therapy, 2017-2031F
- Figure 53. United Kingdom Beta Thalassemia Market Share (%), By Distribution Channel, 2017-2031F
- Figure 54. Russia Beta Thalassemia Market, By Value, in USD Million, 2017-2031F
- Figure 55. Russia Beta Thalassemia Market, By Volume, in Number of Patients, 2017-2031F
- Figure 56. Russia Beta Thalassemia Market Share (%), By Type, 2017-2031F
- Figure 57. Russia Beta Thalassemia Market Share (%), By Therapy, 2017-2031F
- Figure 58. Russia Beta Thalassemia Market Share (%), By Distribution Channel, 2017-2031F
- Figure 59. Netherlands Beta Thalassemia Market, By Value, in USD Million, 2017-2031F
- Figure 60. Netherlands Beta Thalassemia Market, By Volume, in Number of Patients, 2017-2031F
- Figure 61. Netherlands Beta Thalassemia Market Share (%), By Type, 2017-2031F
- Figure 62. Netherlands Beta Thalassemia Market Share (%), By Therapy, 2017-2031F
- Figure 63. Netherlands Beta Thalassemia Market Share (%), By Distribution Channel, 2017-2031F
- Figure 64. Spain Beta Thalassemia Market, By Value, in USD Million, 2017-2031F
- Figure 65. Spain Beta Thalassemia Market, By Volume, in Number of Patients, 2017-2031F
- Figure 66. Spain Beta Thalassemia Market Share (%), By Type, 2017-2031F
- Figure 67. Spain Beta Thalassemia Market Share (%), By Therapy, 2017-2031F
- Figure 68. Spain Beta Thalassemia Market Share (%), By Distribution Channel, 2017-2031F
- Figure 69. Turkey Beta Thalassemia Market, By Value, in USD Million, 2017-2031F
- Figure 70. Turkey Beta Thalassemia Market, By Volume, in Number of Patients, 2017-2031F
- Figure 71. Turkey Beta Thalassemia Market Share (%), By Type, 2017-2031F
- Figure 72. Turkey Beta Thalassemia Market Share (%), By Therapy, 2017-2031F
- Figure 73. Turkey Beta Thalassemia Market Share (%), By Distribution Channel, 2017-2031F
- Figure 74. Poland Beta Thalassemia Market, By Value, in USD Million, 2017-2031F
- Figure 75. Poland Beta Thalassemia Market, By Volume, in Number of Patients, 2017-2031F
- Figure 76. Poland Beta Thalassemia Market Share (%), By Type, 2017-2031F
- Figure 77. Poland Beta Thalassemia Market Share (%), By Therapy, 2017-2031F
- Figure 78. Poland Beta Thalassemia Market Share (%), By Distribution Channel, 2017-2031F
- Figure 79. South America Beta Thalassemia Market, By Value, in USD Million, 2017-2031F
- Figure 80. South America Beta Thalassemia Market, By Volume, in Number of Patients, 2017-2031F
- Figure 81. South America Beta Thalassemia Market Share (%), By Type, 2017-2031F
- Figure 82. South America Beta Thalassemia Market Share (%), By Therapy, 2017-2031F
- Figure 83. South America Beta Thalassemia Market Share (%), By Distribution Channel, 2017-2031F
- Figure 84. South America Beta Thalassemia Market Share (%), By Country, 2017-2031F
- Figure 85. Brazil Beta Thalassemia Market, By Value, in USD Million, 2017-2031F
- Figure 86. Brazil Beta Thalassemia Market, By Volume, in Number of Patients, 2017-2031F
- Figure 87. Brazil Beta Thalassemia Market Share (%), By Type, 2017-2031F
- Figure 88. Brazil Beta Thalassemia Market Share (%), By Therapy, 2017-2031F
- Figure 89. Brazil Beta Thalassemia Market Share (%), By Distribution Channel, 2017-2031F
- Figure 90. Argentina Beta Thalassemia Market, By Value, in USD Million, 2017-2031F
- Figure 91. Argentina Beta Thalassemia Market, By Volume, in Number of Patients, 2017-2031F
- Figure 92. Argentina Beta Thalassemia Market Share (%), By Type, 2017-2031F
- Figure 93. Argentina Beta Thalassemia Market Share (%), By Therapy, 2017-2031F
- Figure 94. Argentina Beta Thalassemia Market Share (%), By Distribution Channel, 2017-2031F
- Figure 95. Asia-Pacific Beta Thalassemia Market, By Value, in USD Million, 2017-2031F
- Figure 96. Asia-Pacific Beta Thalassemia Market, By Volume, in Number of Patients, 2017-2031F
- Figure 97. Asia-Pacific Beta Thalassemia Market Share (%), By Type, 2017-2031F
- Figure 98. Asia-Pacific Beta Thalassemia Market Share (%), By Therapy, 2017-2031F
- Figure 99. Asia-Pacific Beta Thalassemia Market Share (%), By Distribution Channel, 2017-2031F
- Figure 100. Asia-Pacific Beta Thalassemia Market Share (%), By Country, 2017-2031F
- Figure 101. India Beta Thalassemia Market, By Value, in USD Million, 2017-2031F
- Figure 102. India Beta Thalassemia Market, By Volume, in Number of Patients, 2017-2031F
- Figure 103. India Beta Thalassemia Market Share (%), By Type, 2017-2031F
- Figure 104. India Beta Thalassemia Market Share (%), By Therapy, 2017-2031F
- Figure 105. India Beta Thalassemia Market Share (%), By Distribution Channel, 2017-2031F
- Figure 106. China Beta Thalassemia Market, By Value, in USD Million, 2017-2031F
- Figure 107. China Beta Thalassemia Market, By Volume, in Number of Patients, 2017-2031F
- Figure 108. China Beta Thalassemia Market Share (%), By Type, 2017-2031F
- Figure 109. China Beta Thalassemia Market Share (%), By Therapy, 2017-2031F
- Figure 110. China Beta Thalassemia Market Share (%), By Distribution Channel, 2017-2031F
- Figure 111. Japan Beta Thalassemia Market, By Value, in USD Million, 2017-2031F
- Figure 112. Japan Beta Thalassemia Market, By Volume, in Number of Patients, 2017-2031F
- Figure 113. Japan Beta Thalassemia Market Share (%), By Type, 2017-2031F
- Figure 114. Japan Beta Thalassemia Market Share (%), By Therapy, 2017-2031F
- Figure 115. Japan Beta Thalassemia Market Share (%), By Distribution Channel, 2017-2031F
- Figure 116. Australia Beta Thalassemia Market, By Value, in USD Million, 2017-2031F
- Figure 117. Australia Beta Thalassemia Market, By Volume, in Number of Patients, 2017-2031F
- Figure 118. Australia Beta Thalassemia Market Share (%), By Type, 2017-2031F
- Figure 119. Australia Beta Thalassemia Market Share (%), By Therapy, 2017-2031F
- Figure 120. Australia Beta Thalassemia Market Share (%), By Distribution Channel, 2017-2031F
- Figure 121. Vietnam Beta Thalassemia Market, By Value, in USD Million, 2017-2031F
- Figure 122. Vietnam Beta Thalassemia Market, By Volume, in Number of Patients, 2017-2031F
- Figure 123. Vietnam Beta Thalassemia Market Share (%), By Type, 2017-2031F
- Figure 124. Vietnam Beta Thalassemia Market Share (%), By Therapy, 2017-2031F
- Figure 125. Vietnam Beta Thalassemia Market Share (%), By Distribution Channel, 2017-2031F
- Figure 126. South Korea Beta Thalassemia Market, By Value, in USD Million, 2017-2031F
- Figure 127. South Korea Beta Thalassemia Market, By Volume, in Number of Patients, 2017-2031F
- Figure 128. South Korea Beta Thalassemia Market Share (%), By Type, 2017-2031F
- Figure 129. South Korea Beta Thalassemia Market Share (%), By Therapy, 2017-2031F
- Figure 130. South Korea Beta Thalassemia Market Share (%), By Distribution Channel, 2017-2031F
- Figure 131. Indonesia Beta Thalassemia Market, By Value, in USD Million, 2017-2031F
- Figure 132. Indonesia Beta Thalassemia Market, By Volume, in Number of Patients, 2017-2031F
- Figure 133. Indonesia Beta Thalassemia Market Share (%), By Type, 2017-2031F
- Figure 134. Indonesia Beta Thalassemia Market Share (%), By Therapy, 2017-2031F
- Figure 135. Indonesia Beta Thalassemia Market Share (%), By Distribution Channel, 2017-2031F
- Figure 136. Philippines Beta Thalassemia Market, By Value, in USD Million, 2017-2031F
- Figure 137. Philippines Beta Thalassemia Market, By Volume, in Number of Patients, 2017-2031F
- Figure 138. Philippines Beta Thalassemia Market Share (%), By Type, 2017-2031F
- Figure 139. Philippines Beta Thalassemia Market Share (%), By Therapy, 2017-2031F
- Figure 140. Philippines Beta Thalassemia Market Share (%), By Distribution Channel, 2017-2031F
- Figure 141. Middle East & Africa Beta Thalassemia Market, By Value, in USD Million, 2017-2031F
- Figure 142. Middle East & Africa Beta Thalassemia Market, By Volume, in Number of Patients, 2017-2031F
- Figure 143. Middle East & Africa Beta Thalassemia Market Share (%), By Type, 2017-2031F
- Figure 144. Middle East & Africa Beta Thalassemia Market Share (%), By Therapy, 2017-2031F
- Figure 145. Middle East & Africa Beta Thalassemia Market Share (%), By Distribution Channel, 2017-2031F
- Figure 146. Middle East & Africa Beta Thalassemia Market Share (%), By Country, 2017-2031F
- Figure 147. Saudi Arabia Beta Thalassemia Market, By Value, in USD Million, 2017-2031F
- Figure 148. Saudi Arabia Beta Thalassemia Market, By Volume, in Number of Patients, 2017-2031F
- Figure 149. Saudi Arabia Beta Thalassemia Market Share (%), By Type, 2017-2031F
- Figure 150. Saudi Arabia Beta Thalassemia Market Share (%), By Therapy, 2017-2031F
- Figure 151. Saudi Arabia Beta Thalassemia Market Share (%), By Distribution Channel, 2017-2031F
- Figure 152. UAE Beta Thalassemia Market, By Value, in USD Million, 2017-2031F
- Figure 153. UAE Beta Thalassemia Market, By Volume, in Number of Patients, 2017-2031F
- Figure 154. UAE Beta Thalassemia Market Share (%), By Type, 2017-2031F
- Figure 155. UAE Beta Thalassemia Market Share (%), By Therapy, 2017-2031F
- Figure 156. UAE Beta Thalassemia Market Share (%), By Distribution Channel, 2017-2031F
- Figure 157. South Africa Beta Thalassemia Market, By Value, in USD Million, 2017-2031F
- Figure 158. South Africa Beta Thalassemia Market, By Volume, in Number of Patients, 2017-2031F
- Figure 159. South Africa Beta Thalassemia Market Share (%), By Type, 2017-2031F
- Figure 160. South Africa Beta Thalassemia Market Share (%), By Therapy, 2017-2031F
- Figure 161. South Africa Beta Thalassemia Market Share (%), By Distribution Channel, 2017-2031F
- Figure 162. By Type Map-Market Size (USD Million) & Growth Rate (%), 2023
- Figure 163. By Therapy Map-Market Size (USD Million) & Growth Rate (%), 2023
- Figure 164. By Distribution Channel Map-Market Size (USD Million) & Growth Rate (%), 2023
- Figure 165. By Region Map-Market Size (USD Million) & Growth Rate (%), 2023
